Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of therapeutics designed to extend life or improve the quality of life for cancer patients. The Company's pipeline consists of Validive, camsirubicin, MNPR-101, MNPR-101 RIT and MNPR-202. Its lead product candidate, Validive is under Phase IIb/III clinical trial for the prevention of chemoradiotherapy (CRT)-induced severe oral mucositis (SOM) in patients with oropharyngeal cancer (VOICE trial). The Company also commenced a United States-based open-label, Phase Ib clinical trial of camsirubicin for the treatment of advanced soft tissue sarcoma (ASTS). Its three preclinical programs include MNPR-101, which targets antibody for the treatment of various cancers; MNPR-101 RIT, which continues development for the treatment of cancer and severe COVID-19 in collaboration; and MNPR-202, an analog of camsirubicin designed to treat doxorubicin and camsirubicin-resistant cancers.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)